National, 19th October 2023: Mestastop Solutions, a biotechnology startup, has raised Rs 4.5cr or $500k in a Pre Series A round led by 92 angels & Malpani Ventures. In 2021 the company had secured a seed funding of Rs 2cr led by IIM Ahmedabad’s CIIE with participation from IKP and angel investors.
Founded by Arnab Roy Chowdhury and Debabani Roy Chowdhury, Mestastop is creating a cancer metastasis focussed platform, which uses wet lab biology and predictive analytics to identify and distinguish unique properties of metastasis and leverage them for drug discovery and patient treatment.
Dr Arnab’s shared “Over the last three years, we have been involved in extensive R&D, which has created novel platforms. We are ready to leap forward and use these platforms for our discovery and diagnostics efforts. I thank all existing investors for supporting us and the incoming investors for sharing our vision and passion. ”
The funds will be used to generate proof of concept data with small molecules around the identified first-in-class targets and also help progress drug repurposing efforts to delay metastasis by identifying probable clinical candidates. New animal models and clinical studies will also be supported, along with strategic business development activities.
Alok from 92 Angels said ”Mestastop is on a noble mission to defeat cancer, a dreaded disease that takes millions of lives every year. 92Angels, a group of investors whose specific goal is to support companies that make a better world, is privileged to be part of Mestastop’s journey”
“We are pleased to back Arnab, Debabani and the team at Mestastop. The company’s vision of developing novel platforms and predictive diagnostics to solve for cancer metastasis resonates well with our thesis at Malpani Ventures to back purpose-driven tech-first founders in healthcare” – said Dr Anirudh Malpani from Malpani Ventures
The global cost of cancer as a disease burden is poised to be around $25Tn by 2050. The spending on treating and research for curing cancer across would hit $400bn by 2030. Of this global drug discovery market size is poised to hit $150-180bn around that time (Source:Globe Newswire). Metastasis in cancer tackles a complex problem and addresses a potential problem that has plagued cancer cure pharmacos for years leading to diminished return on R&D as well.
